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1607-551X/Copyright ª 2014, KaohsiuAbstract Xp11.2 translocation renal cell carcinoma (RCC) is rare and predominantly found in
children and young adults. Because of the property of overexpressed transcription factor E3
(TFE3) fusion protein, immunohistochemical (IHC) staining with TFE3 antibody makes an excel-
lent diagnostic tool. This study analyzed preliminary experiences of eight Xp11.2 translocation
RCCs in our institution between 2007 and 2012. In four males and four females with a mean age
of 28.4 years. Xp11.2 translocation RCCs were diagnosed. TFE3 IHC stain was positive in all tu-
mor specimens. As the initial presentation, four patients suffered from abdominal pain, three
cases had gross hematuria, and one case had hemoptysis caused by existing lung metastasis.
The tumor was located in the right kidney (75%) with mean diameter of 5.85  2.64 cm. Three
cases (38%, 3/8) presented with lymph node metastasis at the time of diagnosis. In five cases
(63%, 5/8), the initial diagnosis was Stage III and IV. Treatment included open surgery (one par-
tial nephrectomy and five radical nephrectomies), cryoablation, immunotherapy, and target
therapy. The mean follow-up time was 32 months. One patient died after 23.4 months of
follow-up. The application of TFE3 IHC stain will improve the diagnostic accuracy for detecting
XP11.2 translocation renal cell carcinoma. Surgery or cryoablation both had excellent prog-
nosis in early stages. Although the disease is believed to be indolent, an increasingly aggressive
clinical course should be kept in mind, especially for children and young adults.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Xp11.2 translocation renal cell carcinoma 403Introduction
Renal translocation carcinomas of the kidney were first
described as aggressive tumors in the pediatric literature
[1]. The renal cell carcinoma (RCC) associated with Xp11.2
translocation / transcription factor E3 (TFE3) gene fusion
was delineated as a distinct entity in the 2004 World
Health Organization renal tumor classification [2]. Large
reports have shown that overall incidence of Xp11.2
translocation RCCs is low (0.9%) and predominantly
occurring in children and young adults younger than 40
years of age, accounting for about one-third of pediatric
RCCs [3e5]. In contrast, conventional clear cell RCCs
make up about 15% of RCCs in children, 53% in young
adults, and 70% in adults [2,6]. However, there are few
large case series reporting this new entity; thus, the
clinical manifestations, biological behavior, histopatho-
logic features, and prognosis are still poorly understood.
Because only a few cases have been described in Taiwan,
we share our preliminary experiences and literature re-
view in the Xp11.2 translocation RCCs as follows, by: (1)
determining the incidence of RCCs associated with the
Xp11.2 translocation and TFE3 expression in our institute;
(2) characterizing its clinical behavior and survival; and
(3) discussing possible treatment and outcome [7].Materials and methods
With Institutional Review Board approval for retrospective
chart review between 2007 and 2012, there were eight
cases in which Xp11.2 translocation RCCs were diagnosed
within 754 unilateral, sporadic RCC cases at our institution.
Further immunohistochemical (IHC) studies with TFE3
staining were performed on tumors found in younger pa-
tients and/or showed microscopic features suspicious of
Xp11.2 translocation RCC. The score of TFE3 IHC stain was
from 0 to 3þ as previously described [8]. A tumor scored as
positive was subdivided into moderate (2þ) and strong
(3þ), based on the staining intensity. Weak to equivocal
(1þ) nuclear staining in combination with no (0) staining
was considered negative for TFE3 expression [8].
The surgical indication is according to the European
Association of Urology (EAU) guidelines, in which partial
nephrectomy for tumors smaller than 7 cm, cryoablation for
tumors smaller than 4 cm, and radical nephrectomy for
tumors larger than 7 cm are suggested. General history,
initial presentation of disease, imaging studies (contrast-
enhanced computed tomography, magnetic resonance im-
aging), and characteristics of the tumor (location, size)
were all recorded [9e13]. The histopathological charac-
teristics (tumor stage, Fuhrman nuclear grade, and score of
TFE3 IHC stain), treatment methods (surgery, immuno-
therapy or target therapy), and clinical outcome were
analyzed.Results
The incidence of Xp11.2 translocation RCC was approx-
imately 1.06% in our series. There were four males and
four females with mean age 28  9.3 years withoutsystemic disease. Demographic and clinical characteris-
tics of the patients are summarized in Table 1. The chief
complaints included abdominal pain in four cases, gross
hematuria in three cases, and hemoptysis in one case.
The tumors were located over the right kidney in six
cases (75%) and on the left side in two cases (25%). The
mean diameter of the tumors was 5.8  2.6 cm and the
mean volume was 80  71 mL. Three cases (37.5%) were
found to have lymph node metastasis at the time of
diagnosis. Two and one cases were at early Stages I and
II, respectively. In five cases (63%, 5/8), the diagnosis of
advanced Stages III and IV was made at the time of
presentation. Treatments and clinical outcomes are
recorded in Table 2. Four cases underwent open surgery
(one partial nephrectomy because the diameter of the
tumor was smaller than 7 cm and the technique
feasible, and four radical nephrectomies because the
tumor was larger than 7 cm or difficult resection
because the tumor was located near the renal hilum)
and three patients received retroperitoneoscopic cryoa-
blation. In the cryotherapy group, an initial diagnosis of
benign tumors by biopsies performed twice was made in
one case (case No. 4). Finally, radical nephrectomy was
done with the definite diagnosis of Xp11.2 translocation
RCC because of tumor progression in size. Case No. 7
chose retroperitoneoscopic cryoablation because of a
small renal tumor (T1a) and a rapid recovery was
needed for the patient to attend the university entrance
examination; she has been cancer-free after 11.6
months of follow-up. One case (No. 6) with initial pre-
sentation of a small renal mass with lung metastasis was
undergoing salvage cryoablation for cytoreductive ther-
apy before further immunotherapy with interleukin-2
(IL-2), and has maintained a stable disease condition
after 15.5 months. The average follow-up period after
treatment was 29.7  20 months (range,11.6e70.2
months). One patient (case No. 2, initial T3aN1) with
retroperitoneal and Virchow lymph node metastasis un-
derwent cytoreductive nephrectomy and immunotherapy
(interferon-a) with a sequence of target therapies
(sunitinib, sorafenib, temsirolimus). However, she
expired after 23.4 months of follow-up with a
progression-free survival time of 14.3 months. The
remaining seven cases were still alive, even though two
developed recurrence in the lymph nodes and one was
stable with lung metastasis.
Because of the limited follow-up period and small case
numbers, there were no significant differentiations among
cancer characteristics and disease-free survival [age (<30,
>30), p Z 0.655; sex , p Z 0.317; BMI (<20, 20e25,>25),
p Z 0.779; largest diameter (<4, 4e7, 7e10), p Z 0.607;
stage, p Z 0.801; and treatment method (open method,
cryotherapy), p Z 0.655].
Microscopically, Xp11.2 translocation RCCs showed
tumor cells arranged in papillary and nested architecture
with voluminous clear to eosinophilic cytoplasm (Fig. 1).
TFE3 IHC stain was performed in all eight cases and all
revealed positive nuclear labeling. The score of TFE3 IHC
stain was 2þ in three tumors and 3þ in the remaining five
tumors. The tumors categorized by Fuhrman grade revealed
Grade 2 in two cases, Grade 3 in four cases, and Grade 4 in
two cases (Table 1).
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404 H.-H. Su et al.Discussion
The Xp11.2 translocation RCC, an uncommon renal carci-
noma arising in children and young adults, was catego-
rized as a new entity in the 2004 World Health
Organization classification of renal tumors. There are
TFE3 gene fusions with PRCC, ASPSCR-1 and PSF at
t(X;1)(p11.2;q21), t(X;17)(p11.2;q25) and
t(X;1)(p11.2;p34), respectively [14,15]. Because of the
property of over-expressed TFE3 fusion protein, IHC
staining with TFE3 antibody makes a useful auxiliary
diagnostic tool to differentiate other subtypes of RCC
morphologically overlapping with translocation RCC
[2,4,8,16]. The microscopic features, including papillary
or nested (alveolar, compact) or mixed architecture,
voluminous eosinophilic to clear cytoplasm, presence of
calcification and hyalinization, and high Fuhrman nuclear
grade, may mimic clear cell or papillary RCC [4,8].
However, there is one report indicating occasional false-
positive or false-negative staining results of TFE3 may
hinder accurate diagnosis [17]. Therefore, another diag-
nostic approach, such as cathepsin-K IHC stain, TFE3 break-
apart fluorescence in situ hybridization (FISH) assay and
reverse transcription polymerase chain reaction (RT-PCR),
might serve as additional utilities for cases with histological
features of translocation RCC but with negative or equiv-
ocal TFE3 immunostaining [17e21].
Adult Xp11.2 translocation RCCs account only for an
incidence of 1.6e5% in all renal neoplasms, but RCCs in
pediatric/young adult (younger than 45 years) had 15%
Xp11.2 translocation RCC in proportion [16,22]. Many adult
RCCs do not receive routine TFE3 IHC stains, and are mis-
classified as other subtype of RCCs. The real incidence of
adult Xp11.2 translocation RCCs may be underestimated.
Cryopreservation of tumor samples will help in further cy-
togenetic analysis, RT-PCR, or FISH if it is positive for TFE3
stain. Most adult Xp11.2 translocation RCCs also had poor
prognosis with initial metastasis or early metastasis [23,24].
In our study, in all patients the diagnosis was made at a
younger age (mean 28 years old). Series have reported
mean tumor size ranging from 6.8 to 9.2 cm in the largest
diameter, which is larger than the 5.8 cm in our series
[4,23,25].
The radiological characteristics determine subtype of
RCCs with the degree of enhancement, enhancement
pattern, and the contents of the tumor, such as calcifica-
tion, fat, necrosis, or hemorrhage. The translocation RCCs
have higher attenuating lesions (>40 HU) on unenhanced
computed tomography scan that suggest a tumor with high
cellularity and heterogeneous low attenuating necrotic or
hemorrhagic foci [26]. Because of 73% translocation of RCC
having thick, fibrous capsules, the gradual enhancement
pattern on three-phase contrast-enhanced scans found the
peripheral rim of these tumors to be a fibrotic capsule [27].
Because of the resemblance to papillary RCCs histopatho-
logically and radiologically, the preoperative diagnosis of
Xp11 translocation carcinoma remains a challenge.
The classic triad of renal cancer (abdominal mass, pain,
and hematuria) appeared as the initial symptoms at the
time of diagnosis; in four of eight cases (50%) it presented
as abdominal pain or flank pain and three in eight cases
Table 2 Treatment and prognosis of Xp11.2 translocation renal cell carcinoma.
Case Operative method Immunotherapy Target therapy Overall
survival (mo)
Progression-free
survival (mo)
Recurrent site
1 Radical nephrectomy with
lymphadenectomy
None none 70.2a 70.2a
2 Radical nephrectomy with
lymphadenectomy
Interferon-a Sutent/ Nexavar
/ Temsirolimus
23.4 14.3 Lymph node
3 Radical nephrectomy with
lymphadenectomy
None none 46.0a 46.0a
4 Biopsies two times and then
radical nephrectomy
Interleukin-2 none 34.4a 32.8 Lymph node
5 Partial nephrectomy None none 24.5a 24.5a
6 Retroperitoneoscopic renal
cryoablation with 1 probe
Interleukin-2 none 15.5a 15.5a
7 Retroperitoneoscopic renal
cryoablation with 3 probes
None none 11.6a 11.6a
8 Radical nephrectomy with
lymphadenectomy
None none 12.0a 12.0a
a Still surviving in 32-mo average follow-up period.
Xp11.2 translocation renal cell carcinoma 405(37.5%) as hematuria. Several studies for Xp11 translocation
RCCs are summarized in Table 3. In five of eight cases
(62.5%), the diagnosis of advanced Stage III/IV was made in
our series, which is comparable with other series
(35e73.7%) [4,23,28,29]. Translocation RCC often involves
lymph nodes at the time of diagnosis. Three of eight cases
(38%) had lymph node involvement at the time of diagnosis
in our series, which is compatible with 35.5e43.4% in other
series [4,23,28,30]. The average rate of cancer-specific
death was 19.87% (7.1e31.6%) during an average follow-
up period of 33.14 months (range, 11e61.6 months)
[4,7,16,23,28,29].
Different subtypes of RCCs present different gene fac-
tors and clinical behaviors as presented in Table 4 [31].
Most clear cell RCCs have deletions in the short arm of
chromosome 3 (3p); papillary RCCs are usually found to
have trisomy of chromosomes 7 and 17 and/or loss of the Y
chromosome; chromophobe RCCs usually present losses of
chromosomes 1, 2, 6, 10, 13, and 17 [32]. A study enrolling
75 cases also found 65% of patients with nonetranslocation-
associated RCC were low stage (Stages I/II), whereas 65% of
patients with Xp11.2 translocation RCC were high stageFigure 1. (A) Hematoxylin-eosin stain showing compact papillary
cytoplasm (magnification 250). (B) Nuclear strong labeling for im(Stages III/IV) [33]. In general, Xp11.2 translocation RCC
presents at a higher initial cancer stage (35w73.7%) with
strong trends of regional lymph node involvement or me-
tastases (24.8e85%) and females predominate, compared
to other subtype RCCs [2,4,5,33].
In our series, one patient (case No. 6) with multiple lung
metastases at the beginning of diagnosis received retro-
peritoneoscopic cryoablation and immunotherapy with
high-dose IL-2 (600,000 IU/kg) that produced stationary
lung nodules after 15.5 months of follow-up. Nishida et al.
reported cryoablation of metastatic bone lesion could
reduce lung metastasis [34]. The immune response after
cryoablation may play an important role in the treatment of
RCCs. However, the optimal therapy for metastatic Xp11.2
translocation RCCs remains uncertain. Targeted therapy
with vascular endothelial growth factor (VEGF) inhibitors
such as sunitinib and sorafenib, or the inhibitor of
mammalian target of rapamycin (mTOR) kinase such as
temsirolimus and everolimus, have been reported to pro-
duce effective results for metastatic lesions [35e38]. In this
series, we had only one case receiving serial sunitinib,
sorafenib, and temsirolimus and the progression-freeand nested architecture with voluminous clear to eosinophilic
munohistochemical TFE3 stain (magnification 250).
Table 3 Comparison for characteristics of Xp11 translocation RCC [4,7,16,23,28,29].
Literature review Case Average age (y) Sex (M:F) Size (cm) Stage Surgical treatment Medical treatment Median follow-up
(mo)
Progression-free
survival (mo)
This series 8 28.4 1:1 5.8 (3e9.6) I/II:37%, III/IV:63% RN:4, PN:1 Cryo:3 Targeted therapy: 1
Immunotherapy: 3
29.7 (11e70) 28.4  21
Malouf et al. 54 24 (1e64) 1:1.4 d I/II:65%, III/IV:35% RN þ PN:36 d 19.2 (1e58) 2e9 mo in 7 cases
Camparo et al. 31 24.6 1:1.38 6.9 (2.5e20) I/II:58%, III/IV:42% RN:26, PN:4 d 29.5 (5e92) 26.3 (3e36)
Argani et al. 28 37.3 (22e78) 1:3.66 6.8 (2.1e21) I/II:42.9%, III/IV:57.1% PN:2 Immunotherapy: 1 11 (3e72) 1,1,6 y in 3 cases
Rao et al. 19 14.2 (7e24) 1:1.4 d I/II:26.3%, III/IV:73.7% RN:18, PN:1 d 47.86 (13e79) d
Hung et al. 8 28 (20e49) 1:3 9.2 (4e17) I/II:50%, III/IV:50% RN:7 Chemotherapy,
targeted therapy, or
immunotherapy: 4
d 14 (2e24)
Komai et al. 7 42 (15e59) 1:0.75 8.3 (2e16) I/II:57%, III/IV:43% RN þ PN:7 Targeted therapy,
or immunotherapy: 3
61.6 (9e132) d
Cryo Z cryoablation; PN Z partial nephrectomy; RN Z radical nephrectomy; (d) Z unknown data.
Table 4 Comparison with other subtypes of renal cell carcinomas [4,7,16,23,28,29,31].
Renal cell carcinoma
subtype
Incidence Average
age (y)
Sex (M:F) Initial
diagnosis
of advanced
stage (III/IV)
Initial lymph
node metastasis
Genetic factor Inherited syndromes Inherited gene
Clear cell 70e80% 61.4 1.61:1 24.5% 4.5% e3p, þ5q22, e6q, e8p, e9p, e14q Von Hippel-Lindau (VHL) VHL (3p25-26)
Papillary 10e15% 63.1 2.55:1 19.1% 6.4% þ3q, þ7, þ8, þ12, þ16,
þ17,þ20, eY, trisomy 7 & 17
Papillary type 1 / type 2 c-MET (7q34) / FH
(1q42-43)
Chromophobic 3e5% 60.8 1.32:1 11.3% 0.5% e1, e2, e6, e10, e13, e17, e21 Birt-Hogg-Dube (BHD) BHD (17p11.2)
Xp11.2 translocation 1% 26.6 1:1.84 47.7% 35.5e43.4% t(X;1)(p11.2;q21), t(X;17)(p11.2;q25)
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Xp11.2 translocation renal cell carcinoma 407survival was only 4, 3, and 4 months, respectively. In
comparison with the published results of 5e11-month
progression-free survival of targeted therapy in metasta-
tic renal cell carcinoma [39e42], we did not find effective
results in this case. Immunotherapy was reported to have
poor effect with a combination of interferon-a and IL-2 for
three cases of adult Xp11.2 translocation RCCs [16]. In our
series, however, three cases received immunotherapy (2 IL-
2 and 1 interferon-a) where two cases had progression-free
survival less than 3 months because of lymph node recur-
rence, and one initial case of lung metastasis remains as
stable disease after 15.5 months of follow-up.
The Fuhrman grading system was first introduced in 1982
for the grading schema of RCC based on the morphology
[43]. The grading system is determined on nuclear charac-
teristics and has been proven to be a powerful prognostic
predictor for RCC [43e45]. One report indicated that in
TFE3-positive RCCs the diagnosis of a high Fuhrman grade
(III/IV) was made in 87.5% of cases and the 5-year cancer-
specific survival rate was low (15.6%) [25]. In our study,
six cases (75%) also showed higher Fuhrman grade (III/IV).
There was no significant statistical correlation between
patient survival, either overall or cancer-specific, and
Fuhrman grade (pZ 2.286, pZ 0.233) or score of TFE3 IHC
stain (p Z 0.326, p Z 0.255) in our study; however,
because of the limited case number and relatively short
follow-up period in the current series, the exact relation-
ship between patient survival, TFE3 IHC stain, and Fuhrman
grade may need further investigation.
In conclusion, although the incidence is rare, the diag-
nosis of an Xp11.2 TRCC is based on histological appear-
ance, TFE3 IHC study, and genetic analyses. TFE3 is a highly
sensitive and specific immunohistochemical marker for
screening suspicious tumors for the Xp11.2 translocation
RCC in children and young adults. Because of higher tumor
stage and more lymph node involvement than nonselective
RCC, Xp11.2 translocation RCC with advanced stage has a
poor prognosis even if aggressive surgical intervention is
performed and no optimal medical therapy is administered
for metastasis. Traditional open surgery and minimally
invasive cryotherapy both have a good prognosis in early
stages. Before international multicenter studies including
larger numbers of cases are designed to confirm current
outcomes, optimal treatment strategies for this rare Xp11.2
translocation RCC cannot be determined. Early detection
and complete surgery still remain the standard of care. We
herein present our preliminary experiences for this new and
rare entity of renal cell carcinoma in Taiwan.References
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